Peringatan Keamanan

Patients experiencing and overdose may present with hypocalcemia, fever, hypotension, and taste perversion.L13838 Overdose can be managed by symptomatic and supportive treatment which may include the administration of steroids and intravenous calcium.L13838

Pamidronic acid

DB00282

small molecule approved

Deskripsi

Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid.A203111 Pamidronic acid was first described in the literature in 1977.A203267 The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming more popular.A203111

Pamidronic acid was granted FDA approval on 31 October 1991.L13835

Struktur Molekul 2D

Berat 235.0695
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean elimination half life of pamidronate is 28±7 hours.[L13838]
Volume Distribusi -
Klirens (Clearance) The mean total clearance of pamidronate is 107±50mL/min and the mean renal clearance is 49±28mL/min.[L13838]

Absorpsi

In patients with a creatinine clearance >90mL/min, a 90mg intravenous dose reached a Cmax of 1.92±1.08µg/mL, with a Tmax of 4h, and an AUC of 10.2±6.95µg\*h/mL.A203264 In patients with a creatinine clearance 61-90mL/min, a 90mg intravenous dose reached a Cmax of 1.86±0.50µg/mL, with a Tmax of 4h, and an AUC of 10.7—3.91µg\*h/mL.[A203264 In patients with a creatinine clearance 30-60mL/min, a 90mg intravenous dose reached a Cmax of 1.84±0.58µg/mL, with a Tmax of 4h, and an AUC of 10.1±3.38µg\*h/mL.A203264 In patients with a creatinine clearance <30mL/min, a 90mg intravenous dose reached a Cmax of 1.93±0.53µg/mL, with a Tmax of 4h, and an AUC of 34.0±8.37µg\*h/mL.A203264

Metabolisme

Pamidronate is not metabolized in vivo.L13838

Rute Eliminasi

Pamidronate is exclusively eliminated in the urine.L13838 By 120 hours after administration, 46±16% of the dose has been eliminated in the urine.L13838

Interaksi Obat

875 Data
Deferasirox The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Pamidronic acid is combined with Deferasirox.
Thalidomide The risk or severity of nephrotoxicity can be increased when Thalidomide is combined with Pamidronic acid.
Foscarnet The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Foscarnet.
Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Pamidronic acid.
Tenofovir disoproxil Pamidronic acid may increase the nephrotoxic activities of Tenofovir disoproxil.
Tenofovir alafenamide Pamidronic acid may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir Pamidronic acid may increase the nephrotoxic activities of Tenofovir.
Bevacizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Pamidronic acid.
Lenalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Pamidronic acid.
Sunitinib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Pamidronic acid.
Ranibizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Pamidronic acid.
Fumagillin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Pamidronic acid.
Resveratrol The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Resveratrol is combined with Pamidronic acid.
Halofuginone The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Halofuginone is combined with Pamidronic acid.
Anecortave acetate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave acetate is combined with Pamidronic acid.
Endostatin The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostatin is combined with Pamidronic acid.
Semaxanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Semaxanib is combined with Pamidronic acid.
Squalamine The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Squalamine is combined with Pamidronic acid.
Pazopanib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Pamidronic acid.
Volociximab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Volociximab is combined with Pamidronic acid.
TNP-470 The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Pamidronic acid.
Pomalidomide The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Pamidronic acid.
Roquinimex The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Roquinimex is combined with Pamidronic acid.
Endostar The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Endostar is combined with Pamidronic acid.
Trebananib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Trebananib is combined with Pamidronic acid.
Anecortave The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Pamidronic acid.
Beloranib The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Beloranib is combined with Pamidronic acid.
Brolucizumab The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Pamidronic acid.
Icosapent The risk or severity of gastrointestinal bleeding can be increased when Icosapent is combined with Pamidronic acid.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Pamidronic acid.
Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Indomethacin is combined with Pamidronic acid.
Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Nabumetone is combined with Pamidronic acid.
Ketorolac The risk or severity of gastrointestinal bleeding can be increased when Ketorolac is combined with Pamidronic acid.
Tenoxicam The risk or severity of gastrointestinal bleeding can be increased when Tenoxicam is combined with Pamidronic acid.
Celecoxib The risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Pamidronic acid.
Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Tolmetin is combined with Pamidronic acid.
Rofecoxib The risk or severity of gastrointestinal bleeding can be increased when Rofecoxib is combined with Pamidronic acid.
Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Piroxicam is combined with Pamidronic acid.
Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Fenoprofen is combined with Pamidronic acid.
Valdecoxib The risk or severity of gastrointestinal bleeding can be increased when Valdecoxib is combined with Pamidronic acid.
Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Diclofenac is combined with Pamidronic acid.
Sulindac The risk or severity of gastrointestinal bleeding can be increased when Sulindac is combined with Pamidronic acid.
Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Flurbiprofen is combined with Pamidronic acid.
Etodolac The risk or severity of gastrointestinal bleeding can be increased when Etodolac is combined with Pamidronic acid.
Mefenamic acid The risk or severity of gastrointestinal bleeding can be increased when Mefenamic acid is combined with Pamidronic acid.
Naproxen The risk or severity of gastrointestinal bleeding can be increased when Naproxen is combined with Pamidronic acid.
Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Sulfasalazine is combined with Pamidronic acid.
Phenylbutazone The risk or severity of gastrointestinal bleeding can be increased when Phenylbutazone is combined with Pamidronic acid.
Meloxicam The risk or severity of methemoglobinemia can be increased when Pamidronic acid is combined with Meloxicam.
Carprofen The risk or severity of gastrointestinal bleeding can be increased when Carprofen is combined with Pamidronic acid.
Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Diflunisal is combined with Pamidronic acid.
Salicylic acid The risk or severity of gastrointestinal bleeding can be increased when Salicylic acid is combined with Pamidronic acid.
Meclofenamic acid The risk or severity of gastrointestinal bleeding can be increased when Meclofenamic acid is combined with Pamidronic acid.
Acetylsalicylic acid The risk or severity of gastrointestinal bleeding can be increased when Acetylsalicylic acid is combined with Pamidronic acid.
Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Oxaprozin is combined with Pamidronic acid.
Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Ketoprofen is combined with Pamidronic acid.
Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Balsalazide is combined with Pamidronic acid.
Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Ibuprofen is combined with Pamidronic acid.
Olsalazine The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Olsalazine.
Lumiracoxib The risk or severity of gastrointestinal bleeding can be increased when Lumiracoxib is combined with Pamidronic acid.
Magnesium salicylate The risk or severity of gastrointestinal bleeding can be increased when Magnesium salicylate is combined with Pamidronic acid.
Salsalate The risk or severity of gastrointestinal bleeding can be increased when Salsalate is combined with Pamidronic acid.
Choline magnesium trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Choline magnesium trisalicylate is combined with Pamidronic acid.
Antrafenine The risk or severity of gastrointestinal bleeding can be increased when Antrafenine is combined with Pamidronic acid.
Aminophenazone The risk or severity of gastrointestinal bleeding can be increased when Aminophenazone is combined with Pamidronic acid.
Antipyrine The risk or severity of gastrointestinal bleeding can be increased when Antipyrine is combined with Pamidronic acid.
Tiaprofenic acid The risk or severity of gastrointestinal bleeding can be increased when Tiaprofenic acid is combined with Pamidronic acid.
Etoricoxib The risk or severity of gastrointestinal bleeding can be increased when Etoricoxib is combined with Pamidronic acid.
Taxifolin The risk or severity of gastrointestinal bleeding can be increased when Taxifolin is combined with Pamidronic acid.
Oxyphenbutazone The risk or severity of gastrointestinal bleeding can be increased when Oxyphenbutazone is combined with Pamidronic acid.
Licofelone The risk or severity of gastrointestinal bleeding can be increased when Licofelone is combined with Pamidronic acid.
Nimesulide The risk or severity of gastrointestinal bleeding can be increased when Nimesulide is combined with Pamidronic acid.
Benoxaprofen The risk or severity of gastrointestinal bleeding can be increased when Benoxaprofen is combined with Pamidronic acid.
Metamizole The risk or severity of nephrotoxicity can be increased when Pamidronic acid is combined with Metamizole.
Zomepirac The risk or severity of gastrointestinal bleeding can be increased when Zomepirac is combined with Pamidronic acid.
Cimicoxib The risk or severity of gastrointestinal bleeding can be increased when Cimicoxib is combined with Pamidronic acid.
Lornoxicam The risk or severity of gastrointestinal bleeding can be increased when Lornoxicam is combined with Pamidronic acid.
Aceclofenac The risk or severity of gastrointestinal bleeding can be increased when Aceclofenac is combined with Pamidronic acid.
Zaltoprofen The risk or severity of gastrointestinal bleeding can be increased when Zaltoprofen is combined with Pamidronic acid.
Azapropazone The risk or severity of gastrointestinal bleeding can be increased when Azapropazone is combined with Pamidronic acid.
Parecoxib The risk or severity of gastrointestinal bleeding can be increased when Parecoxib is combined with Pamidronic acid.
Salicylamide The risk or severity of gastrointestinal bleeding can be increased when Salicylamide is combined with Pamidronic acid.
Kebuzone The risk or severity of gastrointestinal bleeding can be increased when Kebuzone is combined with Pamidronic acid.
Isoxicam The risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Pamidronic acid.
Indoprofen The risk or severity of gastrointestinal bleeding can be increased when Indoprofen is combined with Pamidronic acid.
Ibuproxam The risk or severity of gastrointestinal bleeding can be increased when Ibuproxam is combined with Pamidronic acid.
Floctafenine The risk or severity of gastrointestinal bleeding can be increased when Floctafenine is combined with Pamidronic acid.
Fenbufen The risk or severity of gastrointestinal bleeding can be increased when Fenbufen is combined with Pamidronic acid.
Etofenamate The risk or severity of gastrointestinal bleeding can be increased when Etofenamate is combined with Pamidronic acid.
Epirizole The risk or severity of gastrointestinal bleeding can be increased when Epirizole is combined with Pamidronic acid.
Benzydamine The risk or severity of gastrointestinal bleeding can be increased when Benzydamine is combined with Pamidronic acid.
Dexibuprofen The risk or severity of gastrointestinal bleeding can be increased when Dexibuprofen is combined with Pamidronic acid.
Dexketoprofen The risk or severity of gastrointestinal bleeding can be increased when Dexketoprofen is combined with Pamidronic acid.
Droxicam The risk or severity of gastrointestinal bleeding can be increased when Droxicam is combined with Pamidronic acid.
Tolfenamic acid The risk or severity of gastrointestinal bleeding can be increased when Tolfenamic acid is combined with Pamidronic acid.
Firocoxib The risk or severity of gastrointestinal bleeding can be increased when Firocoxib is combined with Pamidronic acid.
Clonixin The risk or severity of gastrointestinal bleeding can be increased when Clonixin is combined with Pamidronic acid.
Morniflumate The risk or severity of gastrointestinal bleeding can be increased when Morniflumate is combined with Pamidronic acid.
Propacetamol The risk or severity of gastrointestinal bleeding can be increased when Propacetamol is combined with Pamidronic acid.
Talniflumate The risk or severity of gastrointestinal bleeding can be increased when Talniflumate is combined with Pamidronic acid.

Target Protein

Farnesyl pyrophosphate synthase FDPS
Hydroxylapatite
Geranylgeranyl pyrophosphate synthase GGPS1
Caspase-3 CASP3
Caspase-9 CASP9

Referensi & Sumber

Synthesis reference: Edward C. Shinal, "Method for preparation of disodium pamidronate." U.S. Patent US6268524, issued February, 1988.
Artikel (PubMed)
  • PMID: 16369966
    Zarychanski R, Elphee E, Walton P, Johnston J: Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5.
  • PMID: 30650219
    Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RGG: Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019 Jun;85(6):1052-1062. doi: 10.1111/bcp.13867. Epub 2019 Feb 28.
  • PMID: 18214569
    Russell RG, Watts NB, Ebetino FH, Rogers MJ: Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8.
  • PMID: 9145236
    Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T: Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997 May;20(5):399-404.
  • PMID: 23044853
    Miwa A, Takezako N, Hayakawa H, Hayakawa M, Tominaga S, Yanagisawa K: YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. Am J Hematol. 2012 Dec;87(12):1084-8. doi: 10.1002/ajh.23328. Epub 2012 Oct 9.
  • PMID: 19101859
    Ullen A, Schwarz S, Lennartsson L, Kalkner KM, Sandstrom P, Costa F, Lennernas B, Linder S, Nilsson S: Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol. 2009;43(2):98-103. doi: 10.1080/00365590802475904.
  • PMID: 16298452
    Wada A, Fukui K, Sawai Y, Imanaka K, Kiso S, Tamura S, Shimomura I, Hayashi N: Pamidronate induced anti-proliferative, apoptotic, and anti-migratory effects in hepatocellular carcinoma. J Hepatol. 2006 Jan;44(1):142-50. doi: 10.1016/j.jhep.2005.09.022. Epub 2005 Nov 9.
  • PMID: 9115053
    Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997 Apr;37(4):285-90. doi: 10.1002/j.1552-4604.1997.tb04304.x.
Menampilkan 8 dari 9 artikel.

Contoh Produk & Brand

Produk: 62 • International brands: 3
Produk
  • Aredia
    Injection, powder, lyophilized, for solution • 30 mg/10mL • Intravenous • US • Approved
  • Aredia
    Injection, powder, lyophilized, for solution • 90 mg/10mL • Intravenous • US • Approved
  • Aredia
    Powder, for solution • 60 mg / vial • Intravenous • Canada • Approved
  • Aredia 30mg
    Powder, for solution • 30 mg / vial • Intravenous • Canada • Approved
  • Aredia 90mg
    Powder, for solution • 90 mg / vial • Intravenous • Canada • Approved
  • Aredia Liq Inj 3mg/ml
    Liquid • 3 mg / mL • Intravenous • Canada • Approved
  • Pamidronate Disodium
    Injection • 3 mg/1mL • Intravenous • US • Approved
  • Pamidronate Disodium
    Injection • 9 mg/1mL • Intravenous • US • Approved
Menampilkan 8 dari 62 produk.
International Brands
  • Aminomux
  • Pamimed
  • Ribodroat

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul